Table 6.

Least square means of the most relevant parameters from the tolerance study in chickens for fattening fed the final combination of lasalocid A sodium and nicarbazin compared to the control group1

	Control	1x	1.5x	2x	3x
Lasalocid A sodium + nicarbazin (mg/kg feed)
Intended	0	50 + 50	75 + 75	100 + 100	150 + 150
Analysed, starter		59.7 + 54.4	87.6 + 80.0	116 + 117	174 + 169
Analysed, grower		48.6 + 47.1	71.9 + 71.1	100 + 96.0	151 + 144
Analysed finisher 1		52.3 + 47.3	81.4 + 74.9	107 + 102	152 + 137
Mortality 2
Total mortality (n)	3	13*	18*	14*	29*
Potentially treatment related mortality (n)3	4	7	8	6	17
Performance parameters
Final body weight (g)	2,599	2,554	2,417*	2,268*	1,637*
Average feed intake (g/d)	90	89	85*	81*	63*
Adjusted average feed to gain ratio	1.52	1.54*	1.57*	1.60*	1.74*
Haematology
Mean corpuscular haemoglobin (pg)	43.4	44.1	44.6*	45.7*	46.0*
Mean corpuscular volume (fl)	122.0	122.6	122.7	124.7	127.0*
Serum Chemistry
Total cholesterol (mg/dL)	135	149	154*	157*	187*
Albumin (g/dL)	1.2	1.2	1.3	1.3	1.5*
Magnesium (mg/dL)	2.3	2.4	2.3	2.3	2.6*
Sodium (mmol/L)	163	165	164	162	169*
Calcium (mg/dL)	9.6	9.6	9.4	9.1*	10.1*
Total protein (g/dL)	3.3	3.5	3.4	3.5	3.9*
Creatine kinase (U/L)	16,673	17,357	17,633	21,358	10,627*
Pathology (organ weight)
Testes (g)	0.49	0.39*	0.37*	0.39*	0.21*
Relative to body weight	0.0184	0.0150	0.0154	0.0166	0.0140
Heart (g)	14.85	13.63	13.14	11.45*	9.76*
Relative to body weight	0.5592	0.54158	0.5419	0.4839	0.7091
Liver (g)	60.09	69.18*	63.98	60.66	44.19*
Relative to body weight	2.2620	2.7228*	2.6437*	2.5555*	2.8548*
Spleen (g)	3.77	3.72	3.28	3.01	2.24*
Relative to body weight	0.1421	0.1478	0.1358	0.1258	0.1439
Brain (g)	2.78	2.82	2.90	2.88	2.65
Relative to body weight	0.1050	0.1111	0.1202*	0.1217*	0.1916*

Nd: not detected.

Values with * in the same row are different (p ≤ 0.05) from control values.

¹40 days duration, 8 replicates per treatment, one bird per replicate for haematology, serum values and pathology.

²n out of 120 for the first week, afterwards out of 80 per treatment group.

³From day 0 to 47.